On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23

Five months ago, Merck & Co. revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar 20. Now, the company is comparing the investigational shot to its old warhorse, Pneumovax 23 (PPSV23).